First American Trust FSB Sells 2,603 Shares of Novo Nordisk A/S $NVO

First American Trust FSB lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 12.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 18,800 shares of the company’s stock after selling 2,603 shares during the quarter. First American Trust FSB’s holdings in Novo Nordisk A/S were worth $1,298,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in NVO. Revolve Wealth Partners LLC grew its holdings in Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after purchasing an additional 200 shares during the last quarter. Kingsview Wealth Management LLC grew its stake in shares of Novo Nordisk A/S by 9.3% during the first quarter. Kingsview Wealth Management LLC now owns 5,404 shares of the company’s stock valued at $375,000 after buying an additional 461 shares during the last quarter. Kestra Private Wealth Services LLC raised its holdings in shares of Novo Nordisk A/S by 22.4% in the first quarter. Kestra Private Wealth Services LLC now owns 59,531 shares of the company’s stock worth $4,134,000 after buying an additional 10,891 shares during the period. OneAscent Financial Services LLC lifted its stake in shares of Novo Nordisk A/S by 75.7% during the 1st quarter. OneAscent Financial Services LLC now owns 9,306 shares of the company’s stock worth $644,000 after acquiring an additional 4,010 shares during the last quarter. Finally, J.W. Cole Advisors Inc. boosted its holdings in Novo Nordisk A/S by 58.3% during the 1st quarter. J.W. Cole Advisors Inc. now owns 16,266 shares of the company’s stock valued at $1,129,000 after acquiring an additional 5,989 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 0.5%

Shares of Novo Nordisk A/S stock opened at $48.52 on Tuesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The stock has a market cap of $216.63 billion, a price-to-earnings ratio of 13.33, a PEG ratio of 2.33 and a beta of 0.65. The firm’s 50-day moving average is $54.44 and its two-hundred day moving average is $60.85. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $112.52.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.74 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on NVO. Dbs Bank upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, August 22nd. Berenberg Bank raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Wednesday, September 17th. TD Cowen decreased their price objective on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, August 19th. UBS Group cut shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 5th. Finally, Rothschild & Co Redburn raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 16th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus target price of $59.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.